DIESSE Diagnostica Senese has signed a commercial agreement with Menarini Silicon Biosystems, a Menarini group subsidiary, to distribute the Chorus TRIO immunometric assay system in the US.
CHORUS TRIO is an easy-to-use single-test multiparametric system that includes compact instruments and consumables for immunometric assays.
Under the terms of the deal, Menarini Silicon Biosystems will be responsible for distributing the assay across the US through its sales and marketing teams.
The CHORUS line is developed and manufactured by DIESSE Diagnostica Senese in Italy.
It provides analytical results in mono-test format and can easily be adapted to the requirements of any clinical analysis laboratory.
DIESSE stated that the CHORUS line’s ease of use and reliability make it ideal for performing small series diagnostic tests while ensuring maximum flexibility in organising the workflow of a clinical laboratory.
DIESSE CEO Massimiliano Boggetti said: “Thanks to the mono-test format, which allows operational efficiency and no waste, even in the case of small test volumes, CHORUS will offer analytical quality, operational reliability and efficiency to Physician Office Laboratories (POLs) and other diagnostic laboratories.
“With the broadest range of immunometric mono-test panels, CHORUS TRIO also features technological innovation and Italian design.”
CHORUS TRIO is a single parametric system that includes all the essential reagents for performing immunometric assays.
Furthermore, it needs minimal manual operation and allows for simultaneous testing.
Menarini Silicon Biosystems president and CEO Fabio Piazzalunga said: “DIESSE CHORUS line is a great choice to make testing easy, immediate and accurate when lab automation is not an option.
“Our goal is to bring this smart platform to the US market and leverage our established competencies for the benefits of healthcare professionals and patients throughout the country.”
In 2020, the company reported positive data from a Phase III STIC CTC study that supported the reliability of using circulating tumour cell (CTC) count to guide therapy choices for patients with metastatic breast cancer.